Literature DB >> 9205859

Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas.

K Stefanaki1, D Rontogianni, C H Kouvidou, S Bolioti, G Delides, A Pantelidaki, F Sotsiou, P Kanavaros.   

Abstract

We have investigated the immunohistochemical expression of p53, mdm2, p21/waf1 and bcl-2 proteins in 31 thymic epithelial tumours comprising five medullary thymomas (MDT), four mixed thymomas (MT), 12 cortical thymomas (CT), eight predominately cortical thymomas (PCT) and two well-differentiated thymic carcinomas (WDTC). We have found p53, mdm2, p21 and bcl-2 protein expression in 25/31, 8/31, 5/31 and 10/31 thymic epithelial tumours, respectively. Coexpression of p53 and mdm2 proteins was found in eight cases (three CT, four PCT and one WDTC). Five of them were also p21 positive and three p21 negative. Discordant p53+/mdm2-/p21- protein expression was found in 19 cases (three MDT, three MT, nine CT, three PCT and one WDTC). Mdm2 and p21 proteins were not expressed in the absence of p53 protein. Coexpression of bcl-2 and p53 proteins was found in seven cases (three MDT, three MT and one WDTC). Eighteen cases were p53+/bcl-2- (10 CT, seven PCT and one WDTC) and three cases (two MDT and one MT) were bcl-2+/p53-. Our findings indicate that in thymomas, p53 expression is more frequently associated with cortical histotypes while bcl-2 expression is strongly associated with medullary and mixed histotypes. In addition, there is an inverse correlation between p53 and bcl-2 protein expression in thymomas. Coexpression of p53/mdm2/p21 proteins may reflect thymomas with wild-type (wt), p53 gene since mdm2 and p21 proteins are inducible by wt p53 gene. However, in view of previous findings that p53 mutation is an early event in thymomas, the possibility of p53 gene mutation with p53-independent mdm2 and p21 expression should be considered in these cases. Discordant p53+/mdm2-/p21- protein expression may represent thymomas with p53 gene mutations unable to activate expression of mdm2 and p21 proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205859     DOI: 10.1046/j.1365-2559.1997.5730805.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Thymic malignancies: from clinical management to targeted therapies.

Authors:  Ronan J Kelly; Iacopo Petrini; Arun Rajan; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

2.  Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.

Authors:  P Kanavaros; K Stefanaki; K Valassiadou; J Vlachonikolis; M Mavromanolakis; M Vlychou; S Kakolyris; V Gorgoulis; M Tzardi; V Georgoulias
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

Review 3.  Expression of cell cycle and apoptosis regulators in thymus and thymic epithelial tumors.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Dimitra Rontogianni; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2015-03-21       Impact factor: 3.984

4.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Authors:  I Petrini; P S Meltzer; P A Zucali; J Luo; C Lee; A Santoro; H S Lee; K J Killian; Y Wang; M Tsokos; M Roncalli; S M Steinberg; Y Wang; G Giaccone
Journal:  Cell Death Dis       Date:  2012-07-19       Impact factor: 8.469

5.  Immunohistological analysis of the jun family and the signal transducers and activators of transcription in thymus.

Authors:  Alexandra Papoudou-Bai; Alexandra Barbouti; Vassiliki Galani; Kalliopi Stefanaki; Panagiotis Kanavaros
Journal:  Anat Res Int       Date:  2015-03-18

Review 6.  Implications of Oxidative Stress and Cellular Senescence in Age-Related Thymus Involution.

Authors:  Alexandra Barbouti; Panagiotis V S Vasileiou; Konstantinos Evangelou; Konstantinos G Vlasis; Alexandra Papoudou-Bai; Vassilis G Gorgoulis; Panagiotis Kanavaros
Journal:  Oxid Med Cell Longev       Date:  2020-02-05       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.